Discussion Forums > Working Towards a Cure

Gene Therapy Receives Approval in Europe.

(1/2) > >>

Andy Battaglia:
Big News about gene therapy.

http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-eu-conditional-marketing-authorization?fbclid=IwAR1l2gasMyEgZEDW01qPytvFOlUHXJF3oQntIitkCXLpRoGIL-dy7_A73Zo


--- Quote ---bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype
ZYNTEGLO is the first gene therapy approved for transfusion-dependent β-thalassemia (TDT)
--- End quote ---

Sagar:
thanks for the update. Lets see whats the cost of treatment.

Sagar:
Bluebird bio has come out with a price tag of USD 1.80 million. This is a huge price tag, so patients in Asian countries can't afford to have this treatment

Andy Battaglia:
I would expect the eventual price to be lower in Asia, just as it is with BMT. IF not, they won't get anywhere in the Asian markets.

sanjuna:
Hi I like to know when this treatment will be available in Asian country, particularly in india.

Navigation

[0] Message Index

[#] Next page